The Federal Public Health Service Act 340B drug discount program is facing numerous challenges from drug manufacturers who are trying to restrict access to 340B drugs. Boehringer Ingelheim is now the 8th drug manufacturer to restrict access to 340B drugs at health centers’ contract pharmacies. We need to take action to ensure that protecting access to 340B remains a top priority for Members of Congress. Reach out to your Member of Congress today and inform and educate them on the importance of 340B! Click here for a 340B one pager and here for a federal overview of 340B to share with your Members of Congress.